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Sunmmary Tumour specimens from 23 patients with thyroid carcinoma, 22 patients with thyroid adenoma, 3
with Graves' disease, and tissues from 8 normal thyroid glands were analyzed by Southern blot hybridization
for the physical state of c-myc and c-fos proto-oncogenes. In 4 patients, both the primary tumour and lymph
node metastases were analyzed. No amplification or rearrangement of the two proto-oncogenes was detected.
Total RNAs were also analyzed. Elevated levels of the 2.4kb c-myc RNA and of the 2.2kb c-fos RNA were
found in 13/23 (57%) and 14/23 (61%) of the cancer patients, respectively. High levels of c-myc transcripts
were more frequently found in thyroid carcinomas with unfavourable prognosis. Concomitant elevated levels
of both c-myc and c-fos RNAs were found in 8 cancers. High levels of c-myc RNA were also found in 1 out
of 22 specimens of adenoma, in 1 specimen of Graves' disease and in 2 normal thyroid glands. High levels of
c-fos RNA were found in 20 of the 22 adenoma samples and in 2 out of 8 normal thyroid tissues. These data
indicate that the overexpression of c-myc and c-fos genes is independent of an alteration of the loci. The high
levels ofc-fos found in adenoma may be associated with the differentiation state of these tumours.
Proto-oncogenes are thought to have regulatory roles in
normal cell proliferation and differentiation. They may
contribute to neoplastic transformation when there is an
alteration in their function [Barbacid, 1986; Alitalo &
Schwab, 1986; Cory, 1986). The two proto-oncogenes c-myc
and c-fos, which encode nuclear proteins, seem to have a
crucial role in the control of cell proliferation. When
quiescent fibroblasts are stimulated by peptide growth
factors, c-fos and c-myc genes are rapidly and transiently
induced (Muiiller et al., 1985; Verma et al., 1985). Studies of
c-fos expression in a variety of cell types and tissues at
different stages of development have suggested that the c-fos
gene product may play a role in cell differentiation (Muiller
et al., 1985; Verma et al., 1985; Mufiller, 1986; Gonda &
Metcalf, 1984). However the characterization of the c-fos
gene has only been carried out in a small number of fresh
human cancers (Mavilio et al., 1986; Lehn et al., 1986). By
contrast, the c-myc gene was found to be rearranged,
amplified and overexpressed in a wide variety of human
cancers (Alitalo & Schwab, 1986; Riou et al,, 1984; Rothberg
et al., 1984; Riou et al., 1985,1987; Guerin et al., 1985;
Erisman et al., 1985; Terrier et al., 1985). It was shown to be
involved in the progression of various cancer (Barbacid,
1986; Little et al., 1983) in particular in cancers of the cervix
(Riou et al., 1985,1987), in which this oncogene is more
frequently amplified and overexpressed in the more advanced
stages (III and IV) than in the earlier ones (I and II).
Long term prognosis of thyroid carcinoma is favourable,
but is modulated by several parameters such as age,
histologic characteristics, sex (Tubiana et al., 1985). The
EORTC prognostic index is a weighted factor which takes
into account most of these parameters (Byar et al., 1979). A
pilot study (Terrier et al., 1985) showed that in one patient
with thyroid carcinoma, there was an overexpression of the
c-myc gene in the anaplastic component, in accordance with
the severe prognosis of this histologic type; in contrast, the
expression of this oncogene was normal in the papillary
component. This prompted us to characterize the c-myc and
c-fos proto-oncogenes in thyroid carcinomas and to analyze
their expression in relation to prognosis and differentiation
(Schlumberger et al., 1980,1986).
Materials and methods
Tissue specimens
Tissue specimens were obtained at thyroidectomy and
immediately frozen in liquid nitrogen. They consisted of 23
specimens of primary thyroid cancers. In 4 of these patients
metastatic lymph nodes were also obtained (Table I); 33 non
malignant thyroid samples were studied as controls (22
adenomas, 3 Graves' disease, 8 normal thyroid glands).
Histological examination of a part of the specimens by
frozen sections allowed the selection of the pathologic part
of the thyroid tissue without normal tissue. Thyroid tissues
were histologically classified according to the WHO
classification (Heidinger & Sobin, 1974).
Isolation ofRNA and DNA
RNA and DNA were extracted from the same tissue sample
corresponding to about 50-200mg of fresh tissue. Frozen
tissues were ground in liquid nitrogen and nucleic acids







thyroidspecimens c-myc RNA c-fos RNA
Carcinomas
Follicular well differentiated 0/1 1/1







Graves' disease 1/3 0/3
Normal thyroid tissues 2/8 2/8
'Elevated levels of c-myc and c-fos transcripts corresponding to
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prepared by the guanidinium thyocyanate method as
described by Maniatis et al. (1982). RNA and DNA were
also prepared from N417 cell line originating from human
small cell lung carcinoma which presents a 47 fold c-myc
amplification and a high level of c-myc RNA (Little et al.,
1983).
Northern blots
Denatured total RNA samples (10 Ig per well) were
fractionated on a 1.2% formaldehyde agarose gel and
transferred to a nitrocellulose filter. The filters were
prehybridized and hybridized in stringent conditions as
previously described (Maniatis et al., 1982). Filters were
dried and exposed at -70°C with a Cronex lightning Plus
intensifying screen (Dupont) for various periods of times to
XAR 5 kodak films.
Slot blots
Nitrocellulose were prepared as previously described and
applied to a slot blot apparatus (Schleicher & Schuell). The
top slot for each sample contained 5,ug of total RNA with
two successive slots being two fold serial dilutions. Only one
RNA concentration was shown in this report (see Figure 3).
The blots were prehybridized, hybridized and washed as
described for Northern blots.
Southern blots
Sample DNAs (5pg) were digested with restriction
endonuclease(s) and fractionated by electrophoresis on 1%
agarose gels. The gels were denatured, treated as previously
described (Maniatis et al., 1982) and DNA transferred to
GeneScreenPlus (Dupont NEN) according to the pre-
scription of manufacturer. The blots were prehybridized,
hybridized and washed as described for Northern blots.
Probes
The probes used were the 1.4 kilobase pair (kb) EcoRI-Clal
fragment of the human c-myc proto-oncogene encompassing
exon 3 (Modjtahedi et al., 1985), the 1.3kb BglII-BglII
fragment of v-fos obtained from pFBJ2 plasmid (Curran et
al., 1982) and the 1.7kb BglII-Xbal DNA fragment of the
human I,h globin pseudogene (Fritsch et al., 1980). The
probes were labelled by 32P-dCTP (3000 Cimmol-1) to a
specific activity of 2-5 x 108 cpm,ug- 1 according to the nick-
translation technique (Maniatis et al., 1982).
Quantitative analysis ofthe c-myc and c-fos proto-oncogenes
The copy number of c-myc and c-fos proto-oncogenes in
DNA samples was evaluated by microdensitometer tracings
of autoradiograms. The f3I globin pseudogene was taken as a
single copy gene internal control (Little et al., 1983) and
used to estimate the copy number of the oncogenes in
normal and tumour tissues. This method has been shown to
allow a reliable quantitative measurement of copy numbers.
Quantitative analysis ofthe c-myc and c-fos gene expression
The expression of proto-oncogenes was analyzed by
Northern blot and slot blot hybridization of total RNA. The
same blots were washed off for oncogene signals and
rehybridized to a murine actin probe (Alonso et al., 1986).
The signal intensity obtained with actin probe was the same
in each slot blot providing a control for RNA quality and
content among samples. The integrity and amount of total
RNA of each sample was measured by a preliminary electro-
phoresis in a 1.2% mini agarose gel after ethidium bromide
staining. Amounts of c-myc transcripts were determined by
densitometer tracings of autoradiograms at different
exposure times. The c-myc RNA of N417 cells was used to
determine the levels of transcripts in thyroid RNA,
considering that the levels of c-myc RNA in those cells
correspond to 30 fold the level found in normal cells
(Little et al., 1983). Carcinomas were considered as over-
expressed when the c-myc RNA level was found to be >3
times the level found in normal cells.
EORTC prognostic index
The EORTC prognostic index for thyroid carcinoma (Byar
et al., 1979) is a simple scoring system obtained by adding to
the age at diagnosis (in years), 12 if male, 10 if medullary or
follicular moderately differentiated, 45 if anaplastic, 10 if
tumour extended beyond the thyroid gland (T3 category), 15
if there is at least one distant metastatic site and 15 in
addition to above if there are multiple distant metastatic
sites. Regional lymph node status is not taken into account
in this model.
Results
The c-myc and c-fos loci were characterized in 12.5 and
9.0kb DNA bands respectively, as expected for human DNA
(Figure 1) (Muller et al., 1985; Verma et al., 1985; Riou et
al., 1984). The human Ih globin pseudogene was detected in
a 7.2kb DNA band. No significant amplification was found
in carcinoma samples nor in other thyroid specimens. No
rearrangement was detected using DNA cleavage by several
restriction enzymes (HindIII, PvuII, ClaI, XbaI). Further-
more, DNA recovered from lymph node metastases in 4 of
these patients provided no evidence of gene amplification or
gene rearrangement.
Total RNAs were analyzed for the expression of c-myc
and c-fos proto-oncogenes by Northern blot hybridization.
Transcripts of 2.4kb and 2.2kb were detected with c-myc
and c-fos probes respectively in all specimens of thyroid
carcinoma, adenoma, Graves' disease and normal thyroid
glands (Figure 2). Two minor bands with a migration close
to that of 18S and 28S ribosomal RNAs were occasionally
detected. Furthermore 13 of the 23 thyroid carcinomas
exhibited high levels of c-myc RNA (Table I) corresponding
to - 3-to-20 fold the level observed in normal human tissues
(lymphocytes, thyroid) (Figure 3). The c-myc RNA levels
were elevated in the 4 lymph node metastases as well as in
the corresponding primary tumours. It was at high levels in
9 of the 18 tumours with lymph node metastases and in 3
out of the 5 tumours without lymph node metastases.
Elevated c-myc RNA levels were also found in 1 out of 22
specimens of adenoma, 1 out of 3 Graves' disease and 2 out
of 8 normal thyroid tissues.
Fourteen of the 23 thyroid carcinomas exhibited high levels
of c-fos RNA. An overexpression of both c-fos and c-myc
genes was found in 8 carcinomas. High levels of c-fos
transcripts were found in 20 of the 22 adenomas and in the
two normal thyroid tissues which contained also high levels
of c-myc RNA.
A relationship has been sought between the overexpression
of these oncogenes and the prognosis of the cancer patients
by using the EORTC prognostic index (Byar et al., 1979).
The c-myc gene was - 2 times more frequently over-
expressed, in patients with an unfavourable EORTC
prognostic index, than in those with a favourable index
(X2 =4.79 P<0.03) (Tables II and III). In contrast, the
expression of the c-fos gene was not related with this index
or with the regional lymph node status (Table III). No
relationship was found between the expression of these two
oncogenes on the one hand, and either the functional
characteristics of the neoplastic tissues such as the capacity
of radioiodine uptake, or previous TSH stimulation (surgery
during thyroxin treatment or after TSH stimulation), on the
other (Table II).ONCOGENES IN THYROID CARCINOMAS 45




Figure 1 Analysis of c-myc and c-fos DNA sequences in thyroid
carcinomas. DNAs (5,g) from N417 cells, lymphocytes, normal
thyroid glands, thyroid adenomas and thyroid carcinomas were
digested with EcoRI restriction endonuclease and were analyzed
by the Southern blot hybridization technique.
(A) The 32P-labeled DNA probes (2.5 x 108 cpmpg- 1) used were
a mixture of human c-myc gene (EcoRI-ClaI DNA fragment)
and human #I globin pseudogene (BglII-XbaI DNA fragment).
The c-myc gene was revealed in the 12.5kb band and f31 globin
pseudogene in the 7.2kb band. a, N417 cells; b, lymphocytes;
c, normal thyroid gland; d, adenoma; e to k, thyroid carcinomas.
Amplification of c-myc gene was observed in N417cells,while no
amplification was detected in the other tissues. Blot was exposed
to Kodak XAR5 film for 48 h.
(B) The c-myc and f3, globin signals ofblot presented in panel A
were washed off and the blot rehybridized with 32P-labeled v-fos
probe (BglIII-BglII fragment). The c-fos gene was revealed in the
9.0kb band.
Sizes of DNA bands were calculated using Aphage DNA
cleaved with HindIII endonuclease as standard.

















Figure 2 Analysis of c-myc and c-fos transcripts in thyroid
carcinomas. a, N417 cell line; b, normal thyroid gland; c, adenoma;
d, lymphocytes; e to k, thyroid carcinomas.
(A) Northern blot after hybridization with the human c-myc
probe (EcoRl-CIalI DNA fragment). c-myc transcripts migrated
in a 2.4kb band. Lanes e to h, carcinomas from patients no. 12,
3, 4, and 17 respectively; lanes i to k, RNA from anaplastic
carcinoma (patient 1) (i, anaplastic area; j, lymph node; k,
papillary area); High levels were found in carcinomas (lanes e
to]).
(B) Same blot after the myc signal was washed off and the blot
rehybridized to the v-fos probe (BglII-BglII DNA fragment).
The c-fos transcripts migrated in a 2.2kb band. High levels were
found in adenoma (lane c) and in carcinomas (lanes f, h and j).
Two c-fos transcripts of sizes 3.2 and 10kb were found in N417
line, the 10kb transcript was not shown (lane a).
Same blot after the c-fos signal was washed off and the blot
rehybridized to the murine actin probe. The actin transcripts
migrated in a 2.0kb band.
Discussion
The present data clearly demonstrate that in fresh thyroid
tissues, either normal or with various benign or malignant
conditions, the structure of c-myc and c-fos proto-oncogenes
is not altered and that these genes are neither amplified nor
rearranged. Moreover no alteration was observed in the four
lymph node metastases.
The c-myc and c-fos gene transcripts from normal or
Figure 3 Slot blot analysis of thyroid RNA. Hybridizations
with samples of 5,ug of total RNA except for N417 line (2.5jug
lane h) are only shown. a, lymphocyte; b to f, thyroid
carcinomas; g, normal thyroid gland; h, N417 line.
(A) Hybridization with the c-myc probe.
(B) Hybridization with the v-fos probe.
(C) Hybridization with the murine actin probe.
Corresponding microdensitometer tracings used to measure the
transcript levels are shown.
malignant tissues migrate as expected for human RNA
(Verma et al., 1985; Muller et al., 1986; Gonda & Metcalf,
1984). These data are at variance with the recent description
of three distinct myc transcripts on a smaller number of
patients studied (Yamashita et al., 1986). High levels of
c-myc transcripts corresponding to about 3-to-20 fold the
normal level were detected in 13 of the 23 thyroid
carcinomas. c-myc overexpression was found two times more
frequently in patients with unfavourable prognostic indi-
cators than in those with a favourable prognostic index in
accordance with what has been demonstrated in carcinomas46 P. TERRIER et al.




Patient Histological EORTC Lymph TSH 131I
no. Age Sex typea index node stimul. uptake c-myc c-fos
1 62 M Anap 129 + - - >5 >5
2 69 M FMD 121 + - - 1 1
3 57 M MTC 119 + - ND >5 >5
4 57 F FMD 117 - + - >5 5
5 71 F FMD 111 + + + 5 1
6 63 M Pap 85 + + - 5 1
7 35 M FMD 82 + + + 5 >5
8 57 M FMD 79 + - ND 4 5
9 64 F Pap 64 - - - 1 1
10 22 M Pap 64 + - + 1 1
11 18 F FMD 58 + + + <1 1
12 57 F Pap 57 - - ND 3 5
13 56 F Pap 56 - - ND 1 5
14 37 F MTC 47 + - ND >5 >5
15 33 M Pap 45 + - + 1 >5
16 32 F Pap 42 + + - 1 1
17 26 F Pap 36 - - - >5 5
18 25 F Pap 35 + - + 1 3
19 22 M FWD 34 + ND 1 5
20 33 F Pap 33 + + + 5 >5
21 27 F Pap 27 + - ND >5 1
22 12 M Pap 24 + + + 3 1
23 22 F Pap 22 + - 1 >5
aAnap: anaplastic; FMD: follicular moderately differentiated; FWD: follicular well
differentiated; Pap: papillary; MTC: medullary thyroid carcinoma. bc-myc and c-fos levels
were evaluated by comparison to levels found in normal tissues, taken as level 1.
Table III C-myc and c-fos expression as a function of
the EORTC prognostic index (Byar et al., 1979)
No. ofpatients with
EORTC elevated transcripts of
prognostic No. of
index patients c-myc c-fos
.66 8 7a 5
<65 15 6b 9
a4 patients died within 10 months after oncogene
analysis; bAll the patients of this series were still alive.
of other primary origins (Riou et al., 1985,1987; Guerin et
al., 1985). In contrast the c-fos gene expression was not
related to the prognostic variables.
Recent studies in rat thyroid carcinoma lines have shown
that TSH stimulates proto-oncogenes expression (Colletta et
al., 1986; Dere et al., 1985,1986; Tramontano et al., 1986).
However in the present study, the overexpression of c-myc
and c-fos genes was not related to previous TSH stimulation.
Furthermore, no relationship was found between the over-
expression of c-fos and functional characteristics (i.e.,
capacity of radioiodine uptake) of the neoplastic tissue.
Unexpectedly elevated levels of c-myc RNA were detected in
one adenoma, one Graves' disease and in two normal
thyroid tissues. Recent data on the c-myc gene expression in
developing human embryos suggest that the c-myc gene
activity is not simply a marker of proliferative activity but
reflects additional tissue-specific gene regulation operating
during human embryogenesis (Pfeiffer-Ohlsson et al., 1985).
Several papers have shown that the high levels of c-myc
RNA observed in some cell lines did not correspond to an
overexpression of the c-myc gene but rather to a greater
stability of the c-myc transcripts (Dani et al., 1984; Rabbitts
et al., 1985). In the present study such a mechanism cannot
be ruled out.
In one patient, the c-fos gene was overexpressed in the
anaplastic component, while c-fos RNA levels were normal
in the papillary component surrounding the anaplastic tissue.
This result was unexpected since c-fos overexpression was
shown to be associated with differentiation in cell systems
(Muller et al., 1985; Verma et al., 1985; Muller, 1986). The
role of c-fos in thyroid tissue remains to be elucidated since
markedly elevat-d levels were also found in adenomas; in
these tissues the hypothesis that c-fos may accompany the
differentiation state of these cells cannot be ruled out.
The regulation of c-myc and c-fos proto-oncogenes in
normal thyroid tissues at different stages of differentiation is
still unknown. It is therefore difficult to assess whether this
overexpression can play a role in tumorigenesis; low levels of
c-fos expression are associated with the transformation of
fibroblasts whereas the c-fos proto-oncogene is highly
expressed in some normal cells, for example in mature
macrophages and in normal amniotic cells (Muller, 1986;
Gonda & Metcalf, 1984). The histological observation of
thyroid sections show that tumoural as well as normal
tissues are weakly associated with macrophages, eliminating
the participation of these cells in the oncogene expression.
In cell lines, the regulation of c-fos expression is complex
(Greenberg et al., 1986) and is modulated by external signals
(Muller et al., 1986). It is not known whether the high levels
of transcripts are associated with high levels of protein
expression as interestingly discussed for cervical cancers
(Hendy-Ibbs et al., 1987). A better understanding of the
significance of these oncogene expressions in thyroid cancer
requires further fundamental research; however the present
data already underline the frequent existence of an over-
expression of c-myc in the most malignant thyroid cancer,
but it is not clear whether this dysregulation of the c-myc
expression is the cause or the consequence of this
malignancy.
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